PacBio Files 2024 10-K, Details Financials
Ticker: PACB · Form: 10-K · Filed: 2025-03-17T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, financials
TL;DR
PACB 2024 10-K filed. Revenue breakdown & R&D costs detailed. Check for future growth signals.
AI Summary
Pacific Biosciences of California, Inc. (PACB) filed its 2024 10-K on March 17, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details revenue from product sales and services, along with research and development activities. Key financial figures and operational highlights for 2024 are presented, alongside risk factors and forward-looking statements relevant to the company's future prospects in the laboratory analytical instruments sector.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Pacific Biosciences' financial health and strategic direction for the fiscal year 2024, impacting investment decisions and market perception.
Risk Assessment
Risk Level: medium — The company operates in a highly competitive and rapidly evolving technological sector, facing risks related to innovation, market adoption, and regulatory changes.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K filing.)
- 1231 — Fiscal Year End (Indicates the end date of the reporting fiscal year.)
- 20250317 — Filing Date (Date the 10-K was officially submitted to the SEC.)
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — Filer
- 2024 (date) — Fiscal Year End
- March 17, 2025 (date) — Filing Date
- Menlo Park, CA (location) — Business Address
- 3826 (number) — Standard Industrial Classification
FAQ
What were the total revenues for Pacific Biosciences in 2024?
The filing indicates revenue figures for the fiscal year ending December 31, 2024, broken down into product and service segments, though specific total dollar amounts are not provided in this excerpt.
What is Pacific Biosciences' Standard Industrial Classification (SIC) code?
Pacific Biosciences of California, Inc. is classified under SIC code 3826, which corresponds to Laboratory Analytical Instruments.
When was this 10-K filing submitted to the SEC?
This 10-K filing was submitted to the SEC on March 17, 2025.
What is the company's primary business address?
The company's business address is 1305 O'Brien Drive, Menlo Park, CA 94025.
What is the SEC file number for Pacific Biosciences?
The SEC file number for Pacific Biosciences of California, Inc. is 001-34899.
From the Filing
0001299130-25-000061.txt : 20250317 0001299130-25-000061.hdr.sgml : 20250317 20250317083207 ACCESSION NUMBER: 0001299130-25-000061 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 130 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250317 DATE AS OF CHANGE: 20250317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25742501 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 10-K 1 pacb-20241231.htm 10-K pacb-20241231 FY 0001299130 False 2024 P20D P20D http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment 0.2045157 0.0465116 http://fasb.org/us-gaap/2024#CostOfRevenue iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares pacb:unit utr:D pacb:vote pacb:period pacb:segment 0001299130 2024-01-01 2024-12-31 0001299130 2024-06-30 0001299130 2025-02-28 0001299130 2024-12-31 0001299130 2024-10-01 2024-12-31 0001299130 us-gaap:InProcessResearchAndDevelopmentMember 2024-01-01 2024-12-31 0001299130 2023-12-31 0001299130 us-gaap:ProductMember 2024-01-01 2024-12-31 0001299130 us-gaap:ProductMember 2023-01-01 2023-12-31 0001299130 us-gaap:ProductMember 2022-01-01 2022-12-31 0001299130 pacb:ServiceAndOtherMember 2024-01-01 2024-12-31 0001299130 pacb:ServiceAndOtherMember 2023-01-01 2023-12-31 0001299130 pacb:ServiceAndOtherMember 2022-01-01 2022-12-31 0001299130 2023-01-01 2023-12-31 0001299130 2022-01-01 2022-12-31 0001299130 us-gaap:CommonStockMember 2021-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001299130 us-gaap:RetainedEarningsMember 2021-12-31 0001299130 2021-12-31 0001299130 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001299130 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001299130 us-gaap:CommonStockMember 2022-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001299130 us-gaap:RetainedEarningsMember 2022-12-31 0001299130 2022-12-31 0001299130 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001299130 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001299130 us-gaap:CommonStockMember 2023-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001299130 us-gaap:RetainedEarningsMember 2023-12-31 0001299130 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001299130 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001299130 us-gaap:CommonStockMember 2024-12-31 0001299130 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001299130 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001299130 us-gaap:RetainedEarningsMember 2024-12-31 0001299130 pacb:AptonAndOmniomeMember 2024-01-01 2024-12-31 0001299130 pacb:AptonAndOmniomeMember 2023-01-01 2023-12-31 0001299130 pacb:Apt